nach oben

vorheriger Artikel Arthritis anders? – Neues zu seronegativen Spon...

Tipp

ANCA-assoziierte Vaskulitiden nach Erreichen einer Remission

Zeitschrift:: rheuma plus > Ausgabe 2/2021

Autor:: Prof. Dr. med. B. Hellmich

» Jetzt Zugang zum Volltext erhalten

Wichtige Hinweise

Erstveröffentlichung in Z Rheumatol 2020. 79:696–701. https://doi.org/10.1007/s00393-020-00828-w

Ohne Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Alberici F, Smith RM, Jones RB et al (2015) Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 54:1153–1160 CrossRef

Chan V, Charles BG, Tett SE (2005) Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol 60:257–264 CrossRef

Chanouzas D, Mcgregor JAG, Nightingale P et al (2019) Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study. BMC Nephrol 20:58 CrossRef

Charles P, Dechartres A, Terrier B et al (2020) Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kez063.029 CrossRef

Charles P, Perrodeau E, Bonnotte B et al (2019) Comparions between long-term and conventional rituximab-maintenance treatments: results of a plecebo-controlled randomized trial. Arthritis & rheumatology (Hoboken, N.J.) 71 (Suppl 10). https://acrabstracts.org/comparison-between-long-termn-and-conventional-rituximab-maintenance-treatments-results-of-a-placebo-controlled-randomized-trial/. Zugegriffen: 30. März 2020

Charles P, Terrier B, Perrodeau E et al (2018) Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77:1143–1149 CrossRef

Csernok E, Hellmich B (2020) Usefulness of vasculitis biomarkers in the era of the personalized medicine. Autoimmun Rev 19(5):102514 CrossRef

Csernok E, Mahrhold J, Hellmich B (2018) Anti-neutrophil cytoplasm antibodies (ANCA): recent methodological advances-lead to new consensus recommendations for ANCA detection. J Immunol Methods 456:1–6 CrossRef

De Groot K, Aries PM, Haubitz M et al (2020) Anti-B-Zell Therapie zur Remissionserhaltung bei Granulomatose mit Polyangiitis und mikroskopischer Polyangiitis. Dtsch Med Wochenschr 145:40–46 CrossRef

10.

De Joode AAE, Sanders JSF, Puechal X et al (2017) Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. Rheumatology. https://doi.org/10.1093/rheumatology/kex281 CrossRefPubMed

11.

Deshayes S, Martin Silva N, Khoy K et al (2019) Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. Rheumatology (Oxford) 58:1731–1739 CrossRef

12.

Faurschou M, Westman K, Rasmussen N et al (2012) Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3472–3477. https://doi.org/10.1002/art.34547 CrossRefPubMed

13.

Flossmann O, Berden A, De Groot K et al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494 CrossRef

14.

Guillevin L, Pagnoux C, Karras A et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780. https://doi.org/10.1056/NEJMoa1404231 CrossRefPubMed

15.

Harper L, Morgan MD, Walsh M et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955–960. https://doi.org/10.1136/annrheumdis-2011-200477 CrossRefPubMed

16.

Hiemstra TF, Walsh M, Mahr A et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304:2381–2388 CrossRef

17.

Jayne D, Blockmans D, Luqmani R et al (2019) Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated Vasculitis: a randomized controlled study. Arthritis Rheumatol 71:952–963 CrossRef

18.

Jones RB, Hiemstra TF, Ballarin J et al (2019) Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis 78:399–405 CrossRef

19.

Karras A, Pagnoux C, Haubitz M et al (2017) Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76:1662–1668 CrossRef

20.

Kronbichler A, Kerschbaum J, Gopaluni S et al (2018) Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 77:1440–1447 CrossRef

21.

Lionaki S, Blyth ER, Hogan SL et al (2012) Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64:3452–3462 CrossRef

22.

Lionaki S, Hogan SL, Jennette CE et al (2009) The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int 76:644–651 CrossRef

23.

Mcclure ME, Wason J, Gopaluni S et al (2019) Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis. J Clin Rheumatol 25:217–223 CrossRef

24.

Mcgeoch L, Twilt M, Famorca L et al (2016) CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. J Rheumatol 43:97–120 CrossRef

25.

Metzler C, Miehle N, Manger K et al (2007) Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology (Oxford) 46:1087–1091 CrossRef

26.

Montante A, Le Bras A, Pagnoux C et al (2019) Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol 37(Suppl 117):137–143 PubMed

27.

Morgan MD, Szeto M, Walsh M et al (2017) Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Res Ther 19:129 CrossRef

28.

Ntatsaki E, Carruthers D, Chakravarty K et al (2014) BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53:2306–2309 CrossRef

29.

Pagnoux C, Mahr A, Hamidou MA et al (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359:2790–2803 CrossRef

30.

Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C et al (2010) Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford) 49:2181–2190 CrossRef

31.

Roberts DM, Jones RB, Smith RM et al (2014) Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 31:173–175

32.

Salmela A, Rasmussen N, Tervaert JWC et al (2017) Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate. Rheumatology (Oxford) 56:965–972 CrossRef

33.

Salmela A, Törnroth T, Poussa T et al (2018) Prognostic factors for survival and relapse in ANCA-associated vasculitis with renal involvement: a clinical long-term follow-up study. Int J Nephrol 2018:1–11. https://doi.org/10.1155/2018/6369814 CrossRef

34.

Schirmer JH, Aries PM, De Groot K et al (2017) S 1 Leitlinie zur Diagnose und Therapie der ANCA-assoziierten Vaskulitiden. Z Rheumatol 76:77–104 CrossRef

35.

Smith R, Jayne D, Merkel P (2019) A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease [abstract]. Arthritis & rheumatology 71. https://acrabstracts.org/abstract/a-randomized-controlled-trial-of-rituximab-versus-azathioprine-after-induction-of-remission-with-rituximab-for-patients-with-anca-associated-vasculitis-and-relapsing-disease/. Zugegriffen: 6. Jan. 2020

36.

Solans-Laqué R, Fraile G, Rodriguez-Carballeira M et al (2017) Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine (Baltimore) 96:e6083 CrossRef

37.

Stegeman CA, Tervaert JW, De Jong PE et al (1996) Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335:16–20 CrossRef

38.

Terrier B, Pagnoux C, Perrodeau E et al (2018) Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 77:1150–1156 CrossRef

39.

Thery-Casari C, Euvrard R, Mainbourg S et al (2020) Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis. Autoimmun Rev 19(5):102505 CrossRef

40.

Vandenbussche C, Bitton L, Bataille P et al (2019) Prognostic value of microscopic hematuria after induction of remission in antineutrophil cytoplasmic antibodies-associated vasculitis. Am J Nephrol 49:479–486 CrossRef

41.

Venhoff N, Effelsberg NM, Salzer U et al (2012) Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. Plos One 7:e37626. https://doi.org/10.1371/journal.pone.0037626 CrossRefPubMedPubMedCentral

42.

Walsh M, Flossmann O, Berden A et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542–548 CrossRef

43.

Walsh M, Merkel PA, Mahr A et al (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 62:1166–1173 CrossRef

44.

Yates M, Watts RA, Bajema IM et al (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594

Titel: ANCA-assoziierte Vaskulitiden nach Erreichen einer Remission
Autor:: Prof. Dr. med. B. Hellmich
Publikationsdatum: 04.01.2021
Schlagwort: Rheumatologie
DOI: https://doi.org/10.1007/s12688-020-00391-x
Verlag: Springer Vienna
Zeitschrift: rheuma plus
Ausgabe 2/2021
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610

Bildnachweise

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

ANCA-assoziierte Vaskulitiden nach Erreichen einer Remission

Ohne Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Ohne Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Bewegungsmangel kann Kniearthrose begünstigen

Rot um die Augen nach Corona-Infektion: ein Alarmsignal?

Ein Schritt in Richtung Normalität?

Knorpelschäden rechtzeitig behandeln

Fibromyalgie – pragmatisch gedacht

Diese Berufe erhöhen das Risiko für Gonarthrose